https://www.live-feeds.com/feed/novo-nordisk-slims-down-name-to-novoContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-nordisk-slims-down-name-to-novohttps://www.live-feeds.com/feed/novo-nordisk-slims-down-name-to-novo#u70255Wed, 16 Sep 2026 11:10:28 +0000Danish pharmaceutical manufacturer Novo Nordisk has shortened its day-to-day identity to Novo after four decades, introducing a visual refresh and a cultural reset. The rebranding coincides with the launch of an oral formulation of its weight-loss treatment Wegovy. The maker of Ozempic and Wegovy faces heightened competition in the anti-obesity sector and increasing pressure from competitor Eli Lilly. Company shares have dropped 15% through 2026 as the firm attempts to reclaim its lost momentum in the lucrative weight-loss drug market.Why it mattersThe corporate overhaul aims to make the brand https://www.live-feeds.com/feed/novo-nordisk-slims-down-name-to-novohttps://www.live-feeds.com/feed/novo-nordisk-slims-down-name-to-novo#u69049Tue, 15 Sep 2026 13:46:54 +0000Danish drugmaker Novo Nordisk has shortened its name to Novo as part of a broader corporate restructuring. The company is introducing a new visual identity and a cultural reset to regain momentum in the competitive obesity medication market. This rebranding coincides with the launch of an oral version of its obesity drug Wegovy. While the company seeks a revival, its shares have declined 15% in 2026.Why it mattersThe company produces high-demand weight-loss treatments like Ozempic and Wegovy. This shift comes amid intense competition for obesity market share. The move signals a strategic attem